|Bid||18.00 x 1000|
|Ask||18.61 x 1000|
|Day's Range||17.66 - 18.50|
|52 Week Range||4.19 - 23.39|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||62.67|
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced that the full unblinded clinical data set from the company's phase 2 EMPhASIS trial of lead asset, IMU-838, a selective oral DHODH inhibitor, in patients with relapsing-remitting multiple sclerosis (RRMS) is now available and expands on and confirms the company's previously announced positive top-line results. A summary will be presented at the MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting, taking place September 11-13, 2020, online, by Robert J. Fox, M.D., Staff Neurologist, Mellen Center for Multiple Sclerosis, Vice-Chair for Research, Neurologic Institute, Cleveland Clinic, Cleveland, Ohio.
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific and investor conferences in September:
Shares of Immunic (NASDAQ: IMUX) are up by 18% as of 1:30 p.m. EDT on Wednesday, despite the clinical-stage biopharmaceutical company not reporting any news. IMU-838 achieved all its primary and secondary endpoints in the study, and these positive results are one of the main reasons why Piper Sandler analyst Yasmeen Rahimi initiated coverage on the company's stock with an overweight (buy) rating. After all, the clinical trial process is rife with risk and uncertainty, and if one of the company's candidates fails to deliver positive results, its stock will plunge.